Skip to content
Open access

AptCancerDB: A Curated Knowledgebase and Translational Discovery Platform for Anticancer Aptamers

Jul 2026 · bioRxiv · 0 citations · 65 references
Biology

TL;DR

Aptamers are emerging as important molecular recognition ligands in oncology, playing significant roles in cancer diagnostics, targeted therapies, drug delivery systems, and molecular imaging, and the development of next-generation aptamer-based diagnostics and therapeutics.

Abstract

Aptamers are emerging as important molecular recognition ligands in oncology, playing significant roles in cancer diagnostics, targeted therapies, drug delivery systems, and molecular imaging. Numerous aptamers have advanced to clinical trials, indicating their potential for real-world applications; however, existing databases fail to capture that. To bridge this critical gap, we developed AptCancerDB (https://webs.iiitd.edu.in/raghava/aptcancerdb/), a comprehensive, manually curated database of experimentally verified anticancer aptamers. The current release contains 1,941 entries collected from studies published between 2000 and 2025, covering 29 cancer types, approximately 200 cancer cell lines, and direct links to 22 clinical trials. Each entry is annotated with sequence information, target details, cancer type, cell line, SELEX methodology, affinity determination data, chemical modifications, and biological activities. The dataset is dominated by 82.7% ssDNA, reflecting its superior stability and ease of synthesis, while only 16.6% is ssRNA and appears primarily in studies targeting complex intracellular or protein-protein interactions. To facilitate structural analysis, predicted secondary structures, dot-bracket notations, specific structural elements, and minimum free energy values were also included. AptCancerDB integrates a MySQL backend with an ArcadeDB/OpenCypher-based Knowledge Graph, enabling exploration of relationships among aptamers, targets, cancer types, cell lines, and functional applications. The platform provides advanced search and browsing facilities, BLASTn-based similarity searching, and GC Calculator. Built on a modern, responsive frontend (React/TypeScript/Tailwind CSS), the platform includes a REST API for data retrieval. By integrating fragmented experimental data into a unified cancer-focused resource, AptCancerDB serves as a valuable resource for comparative analysis, aptamer discovery, and the development of next-generation aptamer-based diagnostics and therapeutics. Highlights Curated knowledge base of experimentally validated anticancer aptamers. AptCancerDB contain therapeutic, tumor-homing and cell-penetrating aptamers. Summarizes clinical progress and translational trends in anticancer aptamer research. Supports rational aptamer design using molecular, functional, and clinical annotations Disease-focused resource for cancer diagnosis, therapy, and drug delivery Teaser AptCancerDB maintains experimentally validated anticancer aptamers relevant to diagnosis, drug delivery, and therapy.

Read PDF

Similar papers

Open access Jul 2026

AptViralDB: A Repository of Experimentally Validated Antiviral Aptamers

AptViralDB, a manually curated database providing comprehensive information on experimentally validated antiviral aptamers against 40 viral species and 104 molecular targets, compiled from literature and existing databases is described.

N. Bajiya, Shivansh Singh, P. S. Gahlot et al. · 0 citations
Aug 2026

AptaNexus: An AI-Driven Platform for Aptamer Data Discovery and Intelligent Interaction.

By combining large-scale, evidence-grounded data with agent-accessible interfaces, AptaNexus makes aptamer information readily accessible across disciplines and, for the first time, provides native AI-agent interoperability.

Fangyuan Zheng, Lingjing Yang, Ji-Lie Kong et al. · 0 citations
Review Open access Aug 2026

Advances in Aptamer Diagnostics Targeting Non-Small-Cell Lung Cancer: A Systematic Review

A review aimed at summarizing current knowledge on the new promising DNA and RNA aptamer-based molecules for NSCLC diagnosis showed that several DNA and RNA aptamers are promising diagnostic tools for NSCLC management.

Lisa Agnello, Ilaria Leone, A. Affinito et al. · 0 citations
Open access Jul 2026

Triptolide targets JUN to reverse cisplatin resistance of ovarian cancer: insights from single-cell transcriptome analysis and machine learning validation

This study developed a comprehensive strategy integrating computational predictions with in vitro experimental validations that reverses CDDP resistance in PROC by downregulating JUN, which dismantles intracellular pro-survival networks.

Chen Wang, Junfeng Guo, Taiyang Ye et al. · 0 citations
Open access Jul 2026

ICBcDrug: An online resource and tool for screening and predicting immunotherapy combination drugs.

ICBcDrug is a freely accessible and valuable resource for advancing ICB combination therapy that integrates 2311 reported or predicted compounds across 18 cancer types and accurately predicted both the efficacy and potential mechanisms of the known ICB enhancer entinostat.

Yu Lin, Wen Sun, Yun Xia et al. · 0 citations
Jul 2026

Capture-SELEX-Derived Low-Nanomolar-Affinity Aptamers for Doxorubicin and Inhibition of Cellular Uptake.

This work employed capture-SELEX, which uses free target molecules in solution without immobilization, to isolate DNA aptamers that specifically recognize doxorubicin and significantly inhibited doxorubicin uptake by HeLa cells, establishing a new generation of anthracycline aptamers.

Meheta Datta, Celine Fidella, Lashaun N. Coote et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.